Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks

Area of Science:

• Pharmacology and Toxicology
• Neuroscience
• Cannabis Science

Background:

• Cannabinoids from Cannabis species are investigated for therapeutic uses in pain, psychiatric, and neurological disorders.
• Evolving cannabis legislation and societal acceptance necessitate balancing individual use with public health concerns.
• Concerns exist regarding potential pharmacokinetic (PK) drug-drug interactions affecting drug absorption, distribution, metabolism, and excretion (ADME).

Purpose of the Study:

• To critically review the main PK interactions of major cannabinoids (THC, CBD, CBN, CBC, CBG).
• To examine interactions with drugs used for neuropathic pain, depression, anxiety, schizophrenia, epilepsy, and cancer.
• To assess interactions with common cardiometabolic treatments like statins, beta-blockers, warfarin, insulin, and metformin.

Main Methods:

• Comprehensive literature review of pharmacokinetic interactions.
• Analysis of drug-drug interactions involving major cannabinoids.
• Focus on ADME changes relevant to clinical practice.

Main Results:

• Cannabinoids can alter the metabolism and efficacy of various prescribed medications.
• Potential for significant interactions with psychotropic and cardiometabolic drugs requires careful consideration.
• Data highlights the complexity of cannabinoid pharmacology in diverse patient populations.

Conclusions:

• Understanding cannabinoid PK interactions is essential for safe and effective co-administration with other drugs.
• Further research is needed to elucidate specific interaction mechanisms and clinical implications.
• Clinical guidance is necessary for managing patients using cannabinoids alongside conventional therapies.